Utilization of initial chemotherapy for newly diagnosed acute myeloid leukemia in the United States.

Utilization of initial chemotherapy for newly diagnosed acute myeloid leukemia in the United States. Blood Adv. 2018 Jun 12;2(11):1277-1282 Authors: Bhatt VR, Shostrom V, Gundabolu K, Armitage JO Abstract The use of chemotherapy in patients with acute myeloid leukemia (AML) is associated with survival benefits and alleviation of symptoms related to AML. Prior studies have demonstrated a lower receipt of chemotherapy with increasing age and comorbidities. We hypothesized that socioeconomic and health system factors also determine the use of chemotherapy. We included 61 775 adults with AML diagnosed between 2003 and 2011 from the National Cancer Database, and performed a multivariable logistic regression model to determine the association between receipt of chemotherapy and several factors. A total of 15 608 patients (25.3%) did not receive chemotherapy. In a multivariable analysis, the likelihood of getting chemotherapy declined with increasing age and comorbidities and among patients with therapy-related and intermediate-/high-risk AML. Other factors associated with a lower likelihood of receiving chemotherapy included receipt of care in nonacademic centers, African American race, lower income status, uninsured or Medicare insurance status, and female sex. Compared with the previous studies, our study is novel because it provides data from a large, unselected cohort of patients diagnosed in the United States in recent years, and ...
Source: Adv Data - Category: Epidemiology Authors: Tags: Blood Adv Source Type: research